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Oxygen saturation targets in infants with bronchiolitis 
(BIDS): a double-blind, randomised, equivalence trial
Steve Cunningham, Aryelly Rodriguez, Tim Adams, Kathleen A Boyd, Isabella Butcher, Beth Enderby, Morag MacLean, Jonathan McCormick, 
James Y Paton, Fiona Wee, Huw Thomas, Kay Riding, Steve W Turner, Chris Williams, Emma McIntosh, Steﬀ  C Lewis, for the Bronchiolitis of 
Infancy Discharge Study (BIDS) group*
Summary
Background The American Academy of Pediatrics recommends a permissive hypoxaemic target for an oxygen 
saturation of 90% for children with bronchiolitis, which is consistent with the WHO recommendations for targets in 
children with lower respiratory tract infections. No evidence exists to support this threshold. We aimed to assess 
whether the 90% or higher target for management of oxygen supplementation was equivalent to a normoxic 94% or 
higher target for infants admitted to hospital with viral bronchiolitis.
Methods We did a parallel-group, randomised, controlled, equivalence trial of infants aged 6 weeks to 12 months of 
age with physician-diagnosed bronchiolitis newly admitted into eight paediatric hospital units in the UK (the 
Bronchiolitis of Infancy Discharge Study [BIDS]). A central computer randomly allocated (1:1) infants, in varying 
length blocks of four and six and without stratiﬁ cation, to be clipped to standard oximeters (patients treated with 
oxygen if pulse oxygen saturation [SpO₂] <94%) or modiﬁ ed oximeters (displayed a measured value of 90% as 94%, 
therefore oxygen not given until SpO₂ <90%). All parents, clinical staﬀ , and outcome assessors were masked to 
allocation. The primary outcome was time to resolution of cough (prespeciﬁ ed equivalence limits of plus or minus 
2 days) in the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN28405428.
Findings Between Oct 3, and March 30, 2012, and Oct 1, and March 29, 2013, we randomly assigned 308 infants to 
standard oximeters and 307 infants to modiﬁ ed oximeters. Cough resolved by 15·0 days (median) in both groups 
(95% CI for diﬀ erence –1 to 2) and so oxygen thresholds were equivalent. We recorded 35 serious adverse events in 
32 infants in the standard care group and 25 serious adverse events in 24 infants in the modiﬁ ed care group. In the 
standard care group, eight infants transferred to a high-dependency unit, 23 were readmitted, and one had a prolonged 
hospital stay. In the modiﬁ ed care group, 12 infants were transferred to a high-dependency unit and 12 were readmitted 
to hospital. Recorded adverse events did not diﬀ er signiﬁ cantly.
Interpretation Management of infants with bronchiolitis to an oxygen saturation target of 90% or higher is as safe and 
clinically eﬀ ective as one of 94% or higher. Future research should assess the beneﬁ ts and risks of diﬀ erent oxygen 
saturation targets in acute respiratory infection in older children, particularly in developing nations where resources 
are scarce.
Funding National Institute for Health Research, Health Technology Assessment programme.
Copyright © Cunningham et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Oxygen saturation targets standardise clinical care in 
patients with acute disease, aiming to maintain tissue 
oxygenation and improve clinical outcomes. No 
randomised clinical trial has assessed oxygen saturation 
targets in management of patients with acute lower 
respiratory infection (LRTI).1 The most common acute 
LRTI in early life is acute viral bronchiolitis, which causes 
about 128 000 hospital admissions each year in the USA 
at an estimated cost of US$1·73 billion.2 Applying 
standard unit cost estimates to annual rates in the UK 
reveals that the annual cost of paediatric bronchiolitis to 
NHS England would be about £83·8 million. This ﬁ gure 
is based on 37 200 cases of paediatric bronchiolitis per 
year3 with an average cost per case of £2254.4 In 2006, 
two evidence-based guidelines for the management of 
bronchiolitis included contrasting recommendations 
for oxygen saturation targets. The UK SIGN guideline 
(SIGN 915) recommended a normoxic pulse oxygen 
saturation (SpO₂) target (≥94%), whereas the American 
Academy of Pediatrics (AAP)6 recommended a permissive 
hypoxaemic SpO₂ target (≥90%; reiterated 20147). The 
AAP’s advice is consistent with WHO’s recommended 
SpO₂ target of 90% and higher in infants with 
LRTI. However, WHO’s recommendation is considered 
pragmatic advice for best use of scarce oxygen availability 
in low-resource settings,8 and neither AAP or WHO 
targets have been tested in a randomised controlled trial.
Despite AAP’s guidance, recommended SpO₂ targets 
for infants with bronchiolitis continue to vary between 
national guideline portals for the USA,9 Europe,10 and 
Australasia. This inconsistency might show clinical 
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hesitance to adopt a lower SpO₂ target for infants than 
is currently recommended for older children with 
pneumonia (≤92%)11 and asthma (<94%),12 or a reticence 
to use hypoxaemic targets provided by expert opinion 
when similar recommendations have been associated 
with unanticipated adverse events once tested in a 
randomised controlled trial.13 We aimed to assess 
whether a target oxygen saturation of 90% or higher 
would be equivalent to 94% or higher for resolution of 
illness in acute viral bronchiolitis. To do this we 
assessed time to resolution of cough, which is 
associated with airway inﬂ ammation and might be 
inﬂ uenced by hypoxia.14,15 Cough is a ubiquitous 
symptom in bronchiolitis consistently identiﬁ ed by 
parents and has a duration well documented in 
many trials.16
Methods
Study design and participants
We did a parallel-group, randomised, controlled, 
equivalence trial at eight paediatric hospitals in the UK 
during two 6-month winter bronchiolitis seasons 
(ﬁ ve centres in season one with three additional centres 
added in season two; appendix p 2). The protocol is 
available online. A health economic cost-eﬀ ectiveness 
analysis was also done and is reported separately.
Infants aged between 6 weeks and 12 months of age 
(corrected for prematurity) who presented to a 
participating hospital emergency department or acute 
assessment area, either by general practice referral or 
spontaneous attendance, were assessed by acute care 
medical staﬀ  for potential trial recruitment. To be 
eligible for recruitment, infants had to have a clinical 
diagnosis of bronchiolitis (consistent with SIGN 91 
Bronchiolitis5) made by receiving acute medical staﬀ  and 
required admission to hospital for supportive care. The 
clinical decision to admit an infant with bronchiolitis 
prompted randomisation to the study. We excluded 
infants who: were preterm (<37 weeks’ gestation) and 
had received oxygen therapy in the past 4 weeks; had 
cyanotic or haemodynamically signiﬁ cant heart disease; 
had cystic ﬁ brosis or interstitial lung disease; had 
documented immune function deﬁ cit; were directly 
admitted to a high dependency or intensive care area; or 
were previously randomised.
South East Scotland Research Ethics Committee 3 
provided multicentre UK ethical approval. Written, 
informed consent was obtained from the parent or legal 
guardian.
Randomisation and masking
We randomly allocated (1:1) infants to a standard pulse 
saturation oximeter or a modiﬁ ed pulse saturation 
oximeter. Randomisation was by a central internet-
based secure password-protected computer. The 
random allocation sequence was generated by computer 
programme at the Edinburgh Clinical Trials Unit, UK. 
Randomisation was by blocks of varying length 
(four and six) without stratiﬁ cation. Infants were 
enrolled by clinicians and research or specialist nurses 
in the hospital emergency department or acute 
assessment area, and group allocation was concealed 
until deﬁ nite enrolment. Clinicians (mostly nursing 
staﬀ ) attached either a standard or modiﬁ ed pulse 
oximeter according to the computer-generated random-
isation code. Oximeters were attached with an interval 
of at least 1 min after removal of the hospital oximeter 
and within 4 h of arrival at hospital, and most typically 
at the point of preparing to transfer from hospital 
emergency department or acute assessment area to a 
hospital ward. Monitors were identical in appearance 
(except for study number). The average diﬀ erence 
between displayed standard and modiﬁ ed oximeter 
values was 2% SpO₂ (appendix p 3). To reduce risk of 
unmasking, oximeters had new study numbers 
allocated for season two. All study staﬀ  involved in 
day-to-day running of the trial, hospital staﬀ , and 
parents were masked to study intervention, as were 
those assessing outcomes. The mask was not broken 
for any infant during the study.
For the protocol see http://www.
clinicaltrials.ed.ac.uk/LinkClick.as
px?ﬁ leticket=YB_4elxWL2Q%3d
&tabid=66
Research in context
Evidence before this study
We searched PubMed and Scopus for clinical trials published in 
English with the terms “oxygen”, “oximetry”, “saturation”, 
“bronchiolitis”, “pneumonia”, and “lower respiratory tract 
infection” in humans (all ages) up to Oct 26, 2014. We could 
identify no randomised controlled trials. A Cochrane systematic 
review of oxygen therapy for lower respiratory tract infection in 
children aged 3 months to 15 years identiﬁ ed no randomised 
controlled trials up to April 30, 2008. An observational study in 
Papua New Guinea (Duke et al, 2008) identiﬁ ed that deaths 
from lower respiratory tract infection were reduced in children 
provided with supplemental oxygen for SpO₂ lower than 90% 
when compared with historical controls.
Added value of this study
To our knowledge, this is the ﬁ rst randomised controlled trial of 
oxygen saturation targets of children with bronchiolitis or any 
lower respiratory tract infection. Providing supplemental oxygen 
to a saturation target of 90% in infants with bronchiolitis was 
safe and clinically eﬀ ective. There was some evidence of better 
outcomes in infants managed to a 90% SpO₂ target.
Implications of all the available evidence
Further trials are warranted of older children with lower 
respiratory infection, and our results suggest that the current 90% 
SpO₂ threshold might be open to investigation, especially in low-
resource settings with little availability of supplemental oxygen. 
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Procedures
Standard pulse oximeters (Rad 8 with LNC 10 patient 
cable, Masimo, CA, USA) measured and displayed 
oxygen saturation in the typical way. Identical-looking 
modiﬁ ed oximeters measured arterial oxygen saturation 
as per standard oximeters, but manufacturer-altered 
internal algorithms provided a non-standard display—
for the range 85–100% the algorithm skewed the 
displayed values so that at a measured value of 90% the 
monitor would display 94%, with smoothed displayed 
values above and below this point (appendix). Staﬀ  were 
instructed to provide supplemental oxygen to infants 
with an SpO₂ of lower than 94%. Therefore, infants with 
modiﬁ ed oximeters would not be given supplemental 
oxygen at a displayed 94% oxygen saturation, but actual 
90% oxygen saturation. Pilot work for the trial 
showed very high variability of SpO₂ improvement in 
bronchiolitis during recovery17 and this information was 
provided to staﬀ  during study education.
Study staﬀ  followed up participants and parents or 
carers during the hospital stay and also by structured 
telephone questionnaire at 7, 14, and 28 days, and 
6 months after randomisation to assess outcomes. To 
maximise accurate recall, we provided parents with study 
cards at discharge to remind them of outcomes that 
would be assessed at each follow-up. Every eﬀ ort was 
made to minimise dropout and non-compliance. We 
measured parental anxiety with the anxiety subscale of 
The Hospital Anxiety and Depression Score (HADS).18 
Viral identiﬁ cation was done with routine PCR or near 
patient testing of nasal secretions.
Discharge from hospital was at the discretion of the 
paediatrician responsible for care; however, we asked 
that study infants be considered eligible and ﬁ t for 
discharge from hospital once they had attained stable 
SpO₂ of 94% or higher continuously for 4 h (including a 
period of sleep) and were feeding orally at 75% or more 
of their expected intake of milk daily. In all other aspects, 
management was according to local paediatric care.
Outcomes
The primary outcome for equivalence was time to 
resolution of cough. Evidence of limits of equivalence 
could not be determined from published data and so we 
used expert opinion from a survey of ten general 
paediatricians from Royal Hospital for Sick Children, 
Edinburgh, UK, as plus or minus 2 days (appendix). 
Cough resolution as determined by parents was noted 
during the routine telephone contacts. Parents were 
reminded at each contact of the information they would 
be asked to provide at the next call and requested to note 
the date of cough resolution on their study card. Subgroup 
analyses were prespeciﬁ ed for length of illness before 
randomisation (0–3 days vs 4 or more), use of antibiotics 
(any vs none), and household smoking (any vs none). 
Further prespeciﬁ ed outcomes assessed for equivalence 
were time to feed adequately (≥75% usual) with limits of 
equivalence of plus or minus 4 h; time to a parental 
perception of back to normal with the limits of equivalence 
plus or minus 2 days; SpO₂ measured at 28 days with 
limits of equivalence of plus or minus 1%. Subgroup 
analyses were prespeciﬁ ed for time to ﬁ t for discharge and 
actual discharge by in-hospital oxygen requirement. After 
a review by the data monitoring committee of data from 
season one for SpO₂ at 28 days, equivalence was identiﬁ ed 
with no safety concerns and further measurement was 
stopped to help with study logistics.
A predetermined statistical analysis plan included an 
assessment of diﬀ erences between the groups for the 
time from randomisation until ﬁ t for discharge and 
actual discharge for all infants admitted with 
bronchiolitis; proportion of infants with health-care 
reattendance (primary care, emergency department, 
readmission; parental phone calls); child well enough to 
attend to childcare (parental phone calls) for days 0–7, 
7–14, and 14–28; and diﬀ erence in parental anxiety score 
at 7, 14, and 28 days and 6 month follow-up. A subgroup 
analysis was made of time from randomisation to ﬁ t for 
discharge and actual discharge from hospital in those 
infants with an oxygen requirement during their stay. We 
did a full economic analysis alongside the trial, to 
calculate the incremental cost and eﬀ ectiveness of the 
90% compared with the 94% oxygen saturation discharge 
procedure in terms of health, social care, and societal 
costs, as well as the clinical and quality-of-life outcome 
measures. The analysis was undertaken from the UK 
NHS perspective, with a sensitivity analysis considering 
societal costs from the parents’ perspective.
Statistical analysis
Sample size was established based on the primary 
outcome of time to resolution of cough after randomi-
sation. An estimate of 544 participants needed was made 
by assumption that there would be no diﬀ erence between 
the treatment groups, with a common SD of 8·3 days 
from Plint and colleagues19 The SD of 8·3 was calculated 
by dividing the IQR by 1·35.19,20 This used a two-sided test 
(overall α of 0·05), with power of 80%, and limits of 
equivalence of 2 days (ie, the diﬀ erence between the 
two groups could be up to 2 days in either direction). To 
allow for skewness in the outcome measure, drop-outs, 
and non-compliance, we aimed to recruit 600 infants. 
There were no preplanned stopping rules.
The primary analysis was done by intention to treat, in 
which we analysed all randomly assigned infants by 
allocated treatment, irrespective of treatment received. 
However, for equivalence outcomes, we also did 
per-protocol analyses of infants who received a pulse 
oximeter analysed by treatment received; ﬁ rm 
conclusions were only declared when intention-to-treat 
and per-protocol analyses agreed. Safety analyses were 
done by intention to treat. The primary analysis was 
unadjusted. All statistical tests were two-sided with 5% 
signiﬁ cance. For all outcomes, we used a complete case 
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analysis, but for some equivalence analyses (time to 
cough resolution and time back to normal), imputation 
was used for the primary analysis, as follows. If a date of 
event was known, it was used. If it was known that the 
event occurred, but the precise date was not known, a 
value was chosen between the date that the event was last 
known to not be present and the date of the follow-up 
when it was present. Then a value was chosen at random 
from patients in the same treatment group whose cough 
stopped in a similar timeframe. If it was known that the 
event had not occurred by 6 months, then the event date 
was taken at random from a uniform distribution capped 
at 200 days.21 If it was known that the event had not 
occurred by the last follow-up done, but the patient was 
not followed to 6 months, then a random value was 
chosen from a uniform distribution starting at the last 
known follow-up point until 200 days. This process was 
repeated 100 times, and the analysis done on each 
dataset. The mean values for the estimate of the median, 
and the estimates of the CI limits were used.
For equivalence outcomes, the diﬀ erence in medians 
(and 95% CIs) between treatments was estimated using a 
non-parametric method.22 The treatments were considered 
equivalent if the 95% CI lay within prespeciﬁ ed 
equivalence limits. For time to re-establish adequate 
feeding, no imputations were necessary. For oxygen 
saturation, we estimated the diﬀ erence in mean oxygen 
saturation by an independent sample t test.
We used logistic regression for binary outcomes, 
poisson regression for counts, normal linear models for 
continuous outcomes, and ANCOVA, adjusting for 
baseline score where relevant data were recorded.
We used SAS version 9.3 for Windows for all analyses. 
The data monitoring committee were all based in the UK. 
They worked to a prespeciﬁ ed data monitoring committee 
charter and convened a meeting on three occasions to 
review unblinded data. A data monitoring committee met 
at the end of season one and recommended the study 
continue as planned. This trial is registered with ISRCTN, 
number ISRCTN28405428.
Role of the funding source
The funder was not involved in the collection, analysis, 
interpretation of data, writing of the report or the decision 
to publish. Masimo provided altered algorithms for study 
oximeters, but was not involved in study design or 
collection, analysis, interpretation of data, writing of the 
report, or the decision to publish. The corresponding 
author had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit 
for publication.
Results
Between Oct 3, and March 30, 2012, and Oct 1, and 
March 29, 2013, we recruited 615 infants of median age 
21·3 weeks (IQR 11·7–31·6). We randomly assigned 
308 infants to be monitored with standard oximeter 
(standard group) and 307 to be monitored with the 
modiﬁ ed oximeters that displayed SpO₂ 90% as SpO₂ 
94% (modiﬁ ed group; ﬁ gure 1). The trial steering 
committee decided to continue to the end of season two, 
which is why the sample size is 615 people instead of 
600 as planned. 
Figure 1: Study proﬁ le
HDU=high-dependency unit. PICU=paediatric intensive care unit. BIDS=Bronchiolitis of Infancy Discharge Study 
(BIDS). ITT=intention to treat.
1643 infants admitted to hospital with
clinical diagnosis of bronchiolitis
317 infants <6 weeks excluded
307 assigned to the modified 
group (ITT population)
308 assigned to the standard 
group (ITT population)
293 in primary outcome ITT analysis296 in primary outcome ITT analysis
291 assessed at 6 months293 assessed at 6 months
12 not included in primary outcome
ITT analysis
1 died
1 withdrawn by clinician
7 lost to follow-up
3 declined further contact
14 not included in primary outcome
ITT analysis
12 lost to follow-up
2 declined further contact
2 did not reach end of study
1 lost to follow-up
1 declined further contact
3 did not reach end of study
1 died
1 lost to follow-up
1 declined further contact
615 randomly assigned
617 consented
722 parents approached for consent
1192 eligible
2 randomised in error
105 declined consent
470 not approached for consent
32 no-one available to give consent
253 not approached—no reason
55 lack of time
130 other
134 infants not eligible
14 preterm and O2 therapy
17 with cyanotic or haemodynamically
significant disease
4 with cystic fibrosis or interstitial
lung disease
3 with documented immune
function defect
56 had direct admission to HDU or PICU
40 were previously recruited to BIDS
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There were protocol deviations relating to the pulse 
oximeters (attached late, removed early, or never 
attached) on 26 occasions in 26 infants in the standard 
group and 31 occasions in 30 infants in the modiﬁ ed 
group. Seven infants were incorrectly attached to a 
standard oximeter when randomised to modiﬁ ed care, 
and one given a modiﬁ ed oximeter when randomised to 
standard care. These infants were analysed in the group 
to which they were allocated in the ITT analysis, but to 
that received in the per protocol analysis. Six standard 
and nine modiﬁ ed pulse oximeters were never attached. 
Baseline characteristics were similar between the 
two groups, apart from the modiﬁ ed group had fewer 
boys and more infants were preterm (table 1). 194 (70%) 
of 278 infants in the standard group and 213 (76%) of 
279 in the modiﬁ ed group tested positive for respiratory 
syncytial virus by PCR or near patient testing.
Median time to cough resolution was 15·0 days in both 
standard and modiﬁ ed groups with a median diﬀ erence of 
1·0 day (95% CI –1 to 2; table 2). This interval and 95% CI 
falls within the prespeciﬁ ed equivalence limits of plus 
and minus 2 days. Both the prespeciﬁ ed complete-case 
analysis for the ITT population and per-protocol analysis 
(n=297 for standard group; n=279 for modiﬁ ed group) had 
a median diﬀ erence of 0 days (95% CI –1 to 2; table 2, 
appendix p 4). Because all intervals fell within the 
prespeciﬁ ed equivalence limits, we consider the groups 
equivalent for the primary outcome. No diﬀ erences of 
note were found in the prespeciﬁ ed subgroup analyses for 
time to cough resolution (appendix p4).
Infants returned to adequate feeding 2·7 h sooner 
(median) in the modiﬁ ed group, with the 95% CI 
(–0·3 to 7) falling outside the prespeciﬁ ed limits of plus 
or minus 4 h. Similarly, infants in the modiﬁ ed group 
were considered back to normal 1 day sooner by parents 
(table 2) with the 95% CI of 0 to 3 also falling outside 
prespeciﬁ ed limits (plus and minus 2 days). These 
ﬁ ndings were not anticipated.
We did a post-hoc analysis for the diﬀ erence between 
time-to-event outcomes using Cox proportional hazards 
regression to estimate the treatment eﬀ ect (HRs given for 
modiﬁ ed vs standard). Time to return to adequate feeding 
gave a HR of 1·22 (95% CI 1·04–1·44, p=0·015), and for 
time back to normal a HR of 1·19 (95% CI 1·00–1·41, 
p=0·043). Thus, we have not proved equivalence for these 
outcomes and suggest that the modiﬁ ed group might 
have beneﬁ ted more.
At day 28, SpO₂ values (median 99%; IQR 97–100) did 
not signiﬁ cantly diﬀ er between the groups, with a mean 
diﬀ erence of 0·111 (95% CI –0·35 to 0·57, p=0·64; 
prespeciﬁ ed limits of agreement plus or minus 1%). 
Supplemental oxygen was provided to 223 (73%) of 305 of 
infants in the standard group and 169 (56%) of 304 in the 
modiﬁ ed group. Oxygen was provided for signiﬁ cantly 
longer in the standard group than the modiﬁ ed group 
(table 2). Infants were also ﬁ t for discharge and were 
discharged signiﬁ cantly sooner in the modiﬁ ed group 
(table 2), with beneﬁ t to those who required supplemental 
oxygen (ﬁ gure 2).
Serious adverse events and adverse events were recorded 
up to 28 days after randomisation. We recorded 35 serious 
adverse events in 32 infants in the standard care group and 
25 serious adverse events in 24 infants in the modiﬁ ed care 
group. In the 28 days after randomisation 173 adverse 
events were recorded in 144 infants: 89 adverse events in 
75 infants in the standard care group and 84 adverse events 
in 69 infants in the modiﬁ ed care group. No important 
diﬀ erences were noted between group for type of event 
(respiratory, gastrointestinal) or severity (appendix p 5).
The standard care group had eight episodes of 
high-dependency unit admission (in eight infants), 
26 readmissions to hospital (in 23 infants), and one 
prolonged hospital stay. The modiﬁ ed care group had 
13 episodes of high-dependency unit admission (in 
12 infants) and 12 readmissions to hospital (in 12 infants). 
Time to readmission to hospital did not signiﬁ cantly 
diﬀ er between groups; median diﬀ erence was 0·9 days 
(95% CI 0·4–2·0, p=0·8410). The number of health-care 
contacts (primary, emergency, or hospital) up to 28 days 
was similar (table 3).
Resource use of therapies in hospital other than oxygen 
was similar in the two groups. A cost analysis from a UK 
National Health Service (NHS) perspective showed a $496 
(£290) mean cost saving per patient associated with the 
modiﬁ ed oximeters over the study period (appendix). This 
was a statistically insigniﬁ cant result; however, exploring 
the individual components of the total NHS cost, the 
hospital inpatient stay variable was signiﬁ cantly higher in 
the standard group (£1055 compared to £886, p<0·05).
Standard group 
(n=308)
Modiﬁ ed group 
(n=307)
Age (weeks) 21·3 (12·6–31·1) 21·1 (11·1–32·0)
Boys 186 (60%) 166 (54%)
Preterm (<37 weeks’) 28/278 (10%) 45/279 (16%)
Eczema 51/305 (17%) 44/303 (15%)
Food allergy 8/305 (3%) 11/302 (4%)
Household smoking 133/303 (44%) 130/304 (43%)
1 or more siblings 221/304 (73%) 211/304 (69%)
Primary care visits in previous 4 weeks 1 (1–2) 1 (0–2)
Heart rate on arrival (bpm) 159 (146–173) 158 (148–172)
Respiratory rate on arrival (breaths per min) 50 (44–58) 49 (42–58)
Antibiotics on arrival 24/305 (8%) 23/304 (8%)
Bronchodilator on arrival 17/305 (6%) 16/304 (5%)
Length of Illness (days) on arrival 4 (3–5) 4 (3–5)
Apnoea on arrival 3/303 (1%) 3/304 (1%)
SpO2 on arrival (%) 95% (93–97) 95% (93–97)
SpO2 on arrival ≤94% 121/304 (40%) 119/303 (39%)
Data are n (%), n/N (%), or median (IQR). On arrival relates to arrival at the emergency department. Data were missing 
for the following numbers of patients (standard group, modiﬁ ed): primary care attendances (7, 4), heart rate (3, 4), 
respiratory rate (9, 5), length of illness (3, 5), and SpO₂ (4, 4). SpO₂=pulse oxygen saturation.
Table 1: Baseline clinical data
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Early discharge did not result in parents in the modiﬁ ed 
group having greater levels of anxiety at 7, 14, or 28 days 
(appendix). Lead carers discharged home sooner in the 
modiﬁ ed group actually lost fewer hours to usual activities 
than did those in the standard group discharged later, 
with a median gain of 13·5 h by 7 days, 17·3 h by 14 days 
and 16·1 h by 28 days (appendix p 7). Only few children 
were attending child-care at the time of admission, with 
similar times to return to child-care from randomisation 
to 28 days (appendix p 7).
Discussion
In children with acute viral bronchiolitis, the time taken 
for symptoms to resolve was the same whether they were 
managed to a target oxygen saturation of 90% or 94%. As 
might be expected, when managed to a 90% SpO₂ target, 
fewer infants needed oxygen, those that did needed it for 
a shorter duration, and the infants were discharged 
home sooner. Somewhat unexpectedly, we found that 
infants managed to the lower target of 90% might regain 
satisfactory feeding and be back to normal sooner and 
have fewer readmissions to hospital.
The return to adequate oral feeding a median diﬀ erence 
of 2·7 h sooner in the modiﬁ ed group might simply show 
a more assertive approach to oral feeding by staﬀ  when 
infants were considered to have oxygen saturation in the 
normal range. However, feeding diﬃ  culties could also be 
prolonged in infants (obligate nasal breathers) by the 
drying of nasal secretions by oxygen gases and the 
increased resistance to nasal airﬂ ow created by a nasal 
cannula to deliver oxygen. Parents of infants in the 
modiﬁ ed group considered them to return to normal 
health 1 day sooner than did parents of infants in the 
standard group. Although this ﬁ nding might represent a 
time from discharge eﬀ ect, it could also be consistent 
with a previous report of better outcomes in children with 
bronchiolitis when exposed to fewer interventions.23 
Infants were considered by parents to be back to normal 
health sooner than parents reported complete cough 
resolution, presumably denoting that resolving cough is 
one component of being back to normal health but does 
not deﬁ ne it. We did not anticipate that fewer readmissions 
would occur in the modiﬁ ed group because we considered 
these infants would be discharged sooner in the course of 
their illness and therefore more likely to be readmitted. 
The 5% absolute reduction in readmissions for infants at 
day 28 in the modiﬁ ed group (14 fewer admissions) could 
be considered a clinically important diﬀ erence. The 
reasons for diﬀ erential readmission rates can only be 
speculative, but those with a longer stay in hospital might 
have been at greater risk of nosocomial infection or 
possible oxygen toxicity leading to readmission.
The strength of this study is that we provide evidence-
based target oxygen saturation for the management 
of acute bronchiolitis. Guideline-recommended expert 
opinion for permissive hypoxaemic targets has previously 
been associated with poor outcomes when tested 
in randomised trials, prompting the recommended 
saturation target to be raised.13
However, some limitations should be noted. We did no 
assessment of neurocognitive outcomes. Concerns were 
raised after following the AAP recommendation for 
permissive hypoxemia that the practice might aﬀ ect 
neurocognition.24 However mild hypoxaemia seems to 
Figure 2: Time to ﬁ t to discharge by oxygen requirement and group allocation
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Standard group (n=308) Modiﬁ ed group (n=307) Median diﬀ erence* HR estimate† p value
Time to resolution cough (days)‡ 15·0 (10·0 to 42·5); n=296 15·0 (10·0 to 41·0); n=293 1·00 (–1·0 to 2·0) ·· ··
Time feeding returned to ≥75% normal (h)§ 24·1 (6·5 to 62·1); n=304 19·5 (6·3 to 47·2); n=296 2·7 (–0·3 to 7·3) ·· ··
Time back to normal (days)¶ 12·0 (7·0 to 25·0); n=296 11·0 (6·0 to 20·0); n=293 1·0 (0 to 3·0) ·· ··
Time to ﬁ t to discharge (h) 44·2 (18·6 to 87·5); n=283 30·2 (15·6 to 59·7); n=276 ·· 1·46 (1·23 to 1·73) <0·0001
Time to actual discharge (h) 50·9 (23·1 to 93·4); n=303 40·9 (21·8 to 67·3); n=301 ·· 1·28 (1·09 to 1·50) 0·003
Time to no further supplemental oxygen (h) 27·6 (0 to 68·1); n=305 5·7 (0 to 32·4); n=304 ·· 1·37 (1·12 to 1·68) 0·0021
Data are median (IQR); n or estimate of diﬀ erence (95% CI), unless otherwise stated. *Median diﬀ erence is standard–modiﬁ ed (<0 indicates beneﬁ t to standard practice). †HR is standard/modiﬁ ed (<1 indicates 
beneﬁ t to standard practice). ‡Equivalence deﬁ ned as plus or minus 2 days. §Equivalence deﬁ ned as plus or minus 4 h. ¶Equivalence deﬁ ned as plus or minus 2 days. 
Table 2: Clinical outcomes
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have no signiﬁ cant neurocognitive eﬀ ect in children with 
mild or moderate obstructive sleep apnoea older than 
6 months.25 Infants recovering from bronchiolitis supple-
mented to a stable SpO₂ of 90% would have less hypoxia 
over a shorter timescale than that typically seen in those 
with obstructive sleep apnoea, and so the risk to infants in 
our study seem very low or absent. Another limitation is 
that we did not assess safe oxygen saturation for the 
management of children in a primary care or emergency 
department setting; however, the protocol did incorporate 
a pragmatic brief observation period (4 h) with the purpose 
that this trial could provide supportive evidence for a 
future study of safe targets for SpO₂ in bronchiolitis in 
hospital emergency department or acute assessment area 
and primary care. Recent studies suggest that a more 
ﬂ exible approach to SpO₂ in the assessment of bron-
chiolitis in emergency departments should be pursued.26 
Furthermore, in designing a trial to study the eﬀ ects of 
oxygen saturation targets in emergency admissions to 
hospital wards, we had to meet the challenges of high 
levels of recruitment in an acute setting and satisfactory 
masking. Our pilot work27 revealed that 48% of infants 
admitted with bronchiolitis have satisfactory oxygen 
saturation on arrival at the emergency department with 
desaturation after admission. The logistics of recruitment, 
randomisation, and maintained masking of infants who 
were admitted and subsequently desaturated persuaded 
us that observation of the whole population admitted to 
hospital would provide the best opportunity to study this 
proposed policy change. The trial design reported here 
therefore has the eﬀ ect that the intervention is limited to 
those infants in both groups of the trial who were admitted 
to hospital and desaturated below 94% with provision of 
supplemental oxygen (73% standard group). The eﬀ ect of 
the inclusion of infants who were not aﬀ ected by the study 
intervention is diﬃ  cult to estimate, but on a population 
basis the eﬀ ect was equivalent.
Because children in the modiﬁ ed group managed to a 
target of 90% had the same or better outcomes than did 
those managed to a 94% target, the WHO oxygen saturation 
target of 90% might not be the lower limit of tolerance for 
oxygen saturation in acute respiratory disease in children. 
Particularly in low-resource settings, the risk and beneﬁ t 
balance of managing acute respiratory infection at a target 
lower than the current WHO recommended SpO₂ target 
could be considered. However, with increased risk of death 
shown for children with pneumonia and preterm infants 
with chronic lung disease managed at target oxygen 
saturation of lower than 90%,28–30 the ethical boundaries to 
such a study would need careful consideration.31,32
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Standard group 
(n=308)
Modiﬁ ed group 
(n=307)
Mean diﬀ erence 
(95% CI)
Odds ratio (95% CI) p Reduction in events 
per 1000 treated
Adverse events*
Any adverse event 75 (24%) 69 (22%) ·· ·· ·· ··
Respiratory adverse event 49 (16%) 50 (16%) ·· ·· ·· ··
Gastrointestinal adverse event 7 (2%) 12 (4%) ·· ·· ·· ··
Other adverse event 27 (9%) 14 (5%) ·· ·· ·· ··
Safety outcomes
Deaths 2 (1%) 0 ·· ·· ·· ··
Episodes of high dependency care 8 (3%) 13 (4%) ·· ·· ·· ··
Heart rate at discharge (bpm) 133·8 (16·2)† 135·0 (15·7)† –1·16 (–3·70 to 1·37) ·· 0·37 ··
Respiratory rate at discharge (breaths per min) 38·0 (7·9) 38·0 (6·4) 0·09 (–1·05 to 1·23) ·· 0·88 ··
Re-admission to hospital within 7 days (episodes; 
infants [%])
8 (6; 2%) 5 (5; 2%) ·· ·· ·· ··
Re-admission to hospital within 28 days 
(episodes; infants [%])
26 (23; 7%) 12 (12; 4%) ·· ·· ·· ··
Re-attendance health care within 7 days 39/270 (14%) 34/267 (13%) ·· 0·98 (0·65 to 1·49) 0·94 2 (–56 to 45)
Re-attendance health care within 14 days 76/267 (29%) 70/258 (27%) ·· 1·07 (0·73 to 1·57) 0·73 –14 (–88 to 79)
Re-attendance health care after 28 days 127/274 (46%) 128/262 (49%) ·· 0·90 (0·64 to 1·27) 0·56 26 (–99 to 104)
Antibiotics after discharge 24/305 (8%) 10/304 (3%) ·· ·· ·· ··
Data are n (%), mean (SD), n/N (%), or diﬀ erence (95% CI), unless otherwise speciﬁ ed. bpm=beats per min. *See appendix p 5 for more information about adverse events. †n=304.
Table 3: Adverse events (number of patients) and safety outcomes
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